Chitosan as a coating material for nanoparticles intended for biomedical applications

Frank, Luíza Abrahão; Onzi, Giovana R.; Morawski, A.S.; Pohlmann, Adriana Raffin; Guterres, Sílvia Stanisçuaski; Contri, Renata Vidor

doi:10.1016/j.reactfunctpolym.2019.104459

Cited by 181 publications

(114 citation statements)

References 97 publications

Supporting

Mentioning

113

Contrasting

Order By: Relevance

“…Thus, the encapsulation of DFO in biocompatible nanoparticles aiming in a slower and more controlled release of the drug in the blood could provide an alternative means for drug administration, bypassing the compliance issue and improving quality of life. Released DFO should maintain its pharmacological properties, efficacy and safety profile.Chitosan (CS) NPs have attracted a lot of attention as drug delivery vehicles due to their ability to protect the drug from degradation, to achieve higher drug-loading and to release it in a slow and sustained manner [7][8][9][10]. Furthermore, due to the hydrophilic properties of chitosan, CS NPs are suitable carriers for hydrophilic drugs, like DFO.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)

et al. 2020

View full text Add to dashboard Cite

The objective of this study was to develop chitosan (CS) nanoparticles (NPs) loaded with deferoxamine mesylate (DFO) for slow release of this iron-chelating drug. Drug nanoencapsulation was performed via ionic gelation of chitosan using sodium tripolyphosphate (TPP) as cross-linker. Nanoparticles with a size ranging between 150 and 400 nm were prepared for neat CS/TPP with a 2/1 molar ratio while their yield was directly dependent on the applied stirring rate during the preparation process. DFO at different content (20, 45 and 75 wt %) was encapsulated into these nanoparticles. We found that drug loading correlates with increasing DFO content while the entrapment efficiency has an opposite behavior due to the high solubility of DFO. Hydrogen-bonding between amino and hydroxyl groups of DFO with reactive groups of CS were detected using FT-IR spectroscopy while X-ray diffraction revealed that DFO was entrapped in amorphous form in the CS nanoparticles. DFO release is directly dependent on the content of loaded drug, while model analysis revealed that the release mechanism of DFO for the CS/TPP nanoparticles is by diffusion. Treatment of murine RAW 264.7 macrophages with nanoencapsulated DFO promoted an increased expression of transferrin receptor 1 (TfR1) mRNA, a typical homeostatic response to iron deficiency. These data provide preliminary evidence for release of pharmacologically active DFO from the chitosan nanoparticles.Pharmaceutics 2020, 12, 238 2 of 17 the aid of a portable infusion pump at least 4-5 days per week and for 8-10 h each time. This rather strenuous procedure reduces compliance and compromises of quality of life.Nanocarriers, such as biocompatible polymers, offer unique possibilities to overcome cellular barriers and improve drug delivery [2]. Their small sizes allow high diffusivity across membranes improving drug permeability. Nanoparticles (NPs) have a diameter of less than 200 nm and this can facilitate their cellular uptake via receptor-mediated endocytosis, fluid phase endocytosis or even passive diffusion; moreover the small size reduces their clearance by the mononuclear phagocyte system, which in turn increases their circulation time in blood [3][4][5][6]. Thus, the encapsulation of DFO in biocompatible nanoparticles aiming in a slower and more controlled release of the drug in the blood could provide an alternative means for drug administration, bypassing the compliance issue and improving quality of life. Released DFO should maintain its pharmacological properties, efficacy and safety profile.Chitosan (CS) NPs have attracted a lot of attention as drug delivery vehicles due to their ability to protect the drug from degradation, to achieve higher drug-loading and to release it in a slow and sustained manner [7][8][9][10]. Furthermore, due to the hydrophilic properties of chitosan, CS NPs are suitable carriers for hydrophilic drugs, like DFO. Lately, CS NPs have shown promising results in delivering drugs for treatment of diabetes and cancer [11]. In another case, CS NPs were inoculated...

show abstract

mentioning

confidence: 99%

“…Chitosan (CS) NPs have attracted a lot of attention as drug delivery vehicles due to their ability to protect the drug from degradation, to achieve higher drug-loading and to release it in a slow and sustained manner [7][8][9][10]. Furthermore, due to the hydrophilic properties of chitosan, CS NPs are suitable carriers for hydrophilic drugs, like DFO.…”

mentioning

confidence: 99%

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Chitosan and chitosan derivatives have been used in several studies as a coating material to protect insulin-loaded nanoparticles, as it is believed to have a vital role in protecting insulin from premature release in the gastric medium and increase the residence time of nanoparticles at the intestinal mucosa upon reaching the small intestine [ 119 ]. Chitosan coated nanoparticles can be prepared by either addition of chitosan solution into previously prepared nanoparticle formulations, an easy and frequently described way to coat nanoparticles, or by adding chitosan solution during the nanoparticle formation process.…”

Section: Chitosan and Chitosan Derivatives As Coating Materials Formentioning

confidence: 99%

Recent Progress of Chitosan and Chitosan Derivatives-Based Nanoparticles: Pharmaceutical Perspectives of Oral Insulin Delivery

2020

View full text Add to dashboard Cite

Diabetes mellitus is a chronic endocrine disease, affecting more than 400 million people around the world. Patients with poorly controlled blood glucose levels are liable to suffer from life-threatening complications, such as cardiovascular, neuropathy, retinopathy and even premature death. Today, subcutaneous parenteral is still the most common route for insulin therapy. Oral insulin administration is favourable and convenient to the patients. In contrast to injection route, oral insulin delivery mimics the physiological pathway of endogenous insulin secretion. However, oral insulin has poor bioavailability (less than 2%) due to the harsh physiological environment through the gastrointestinal tract (GIT). Over the last few decades, many attempts have been made to achieve an effective oral insulin formulation with high bioavailability using insulin encapsulation into nanoparticles as advanced technology. Various natural polymers have been employed to fabricate nanoparticles as a delivery vehicle for insulin oral administration. Chitosan, a natural polymer, is extensively studied due to the attractive properties, such as biodegradability, biocompatibility, bioactivity, nontoxicity and polycationic nature. Numerous studies were conducted to evaluate chitosan and chitosan derivatives-based nanoparticles capabilities for oral insulin delivery. This review highlights strategies that have been applied in the recent five years to fabricate chitosan/chitosan derivatives-based nanoparticles for oral insulin delivery. A summary of the barriers hurdle insulin absorption rendering its low bioavailability such as physical, chemical and enzymatic barriers are highlighted with an emphasis on the most common methods of chitosan nanoparticles preparation. Nanocarriers are able to improve the absorption of insulin through GIT, deliver insulin to the blood circulation and lower blood glucose levels. In spite of some drawbacks encountered in this technology, chitosan and chitosan derivatives-based nanoparticles are greatly promising entities for oral insulin delivery.

show abstract

“…The raw data are presented in the supporting information ( Figure S1, Table S1). The surface positivity of the synthesized nanoparticles can be attributed to their stabilization with the positively charged chitosan [40]. This increased surface positivity is advantageous both in terms of imparting physical stability, as well as achieving the desired sensitive sensing of the negatively charged LPS and E. coli.…”

Section: Characterization Of Chi-agnpsmentioning

confidence: 99%

Chitosan Stabilized Silver Nanoparticles for the Electrochemical Detection of Lipopolysaccharide: A Facile Biosensing Approach for Gram-Negative Bacteria

et al. 2020

View full text Add to dashboard Cite

Negatively charged lipopolysaccharide (LPS), a major endotoxin and component of the outer membrane of several Gram-negative bacteria, provides a useful biomarker for the indirect detection of these pathogens. For instance, Escherichia coli (E. coli) is a pathogenic bacterium that causes infections in almost all age groups, and has been implicated in food and water contamination. Current diagnostic and detection methods tend to be labor-intensive or expensive, necessitating the need for an easy, sensitive, rapid, and low-cost method. We report on the synthesis and use of positively charged chitosan stabilized silver nanoparticles (Chi-AgNPs) as a sensitive electrochemical nanobiosensor for the detection of LPS. Chi-AgNPs were synthesized through a facile, single step protocol, and characterized for size, charge, and morphology. Glassy carbon electrodes modified with Chi-AgNPs resulted in an enhancement of signal in the presence of both LPS and E. coli. Detection was accomplished over a large concentration range (several orders of magnitude) of 0.001–100 ng/mL and 10–107 CFU/mL. The biosensors can reliably detect LPS and E. coli at very low concentrations. Chi-AgNPs have potential as low cost, sensitive nanobiosensors for Gram-negative bacteria due to strong electrostatic interaction with LPS present in their outer membranes.

show abstract

Chitosan as a coating material for nanoparticles intended for biomedical applications

Cited by 181 publications

References 97 publications

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)

Recent Progress of Chitosan and Chitosan Derivatives-Based Nanoparticles: Pharmaceutical Perspectives of Oral Insulin Delivery

Chitosan Stabilized Silver Nanoparticles for the Electrochemical Detection of Lipopolysaccharide: A Facile Biosensing Approach for Gram-Negative Bacteria

Contact Info

Product

Resources

About